Polypharmacological drug design opportunities against Parkinson's disease

Background: Parkinson's disease is an attractive model to extend research towards a better understanding of the interrelationship between genes and environment (exposome) therefore ideal for polypharmacological approach due its clinical heterogeneity. Methods: In this paper, we present series chemical scaffolds extracted from ChEMBL 30 Database, with two or more targets PD-related proteins obtained through chemoinformatics methods. This way, describe first adaptation Dual Activity Difference (DAD) map that allows direct identification "dual activity cliffs". Results: We identified 25 antiparkinson small molecules whose pharmacological are directed dopaminergic muscarinic acetyl choline M1-M5 receptors; 2 three norepinephrine transporter, D1-D2 6 both transporter receptors 1 adenosine A2a Dopamine D1-D5 receptors. Conclusion: Chemoinformatics methods 36 related disease. Demonstrating design drugs opportunity in PD.